Antifungal management in cancer patients

Wiener Medizinische Wochenschrift

Volumn 157, Issue 19-20, 2007, Pages 503-510

  Staber, Philipp ^a   Langner, Stefan ^a   Dornbusch, Hans Jürgen ^a   Neumeister, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antifungal treatment; Haematological malignancies; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CANCER PATIENT; CANDIDIASIS; HUMAN; MORBIDITY; MORTALITY; MYCOSIS; REVIEW;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CAUSE OF DEATH; CHILD; FUNGEMIA; HUMANS; LUNG DISEASES, FUNGAL; MYCOSES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PREMEDICATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 36049024395     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0466-y     Document Type: Review

References (62)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34: 909-917
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317
3. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26: 781-803; quiz 804-785
4. Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100: 4358-4366
5. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32: 358-366
6. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ (2003) Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 438-472
7. Martino R, Subira M, Rovira M et al (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 116: 475-482
8. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46: 1581-1582
9. Wingard JR, Leather H (2004) A new era of antifungal therapy. Biol Blood Marrow Transplant 10: 73-90
10. Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25: 419-425
11. Mora-Duarte J, Betts R, Rotstein C et al ((2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347: 2020-2029
12. Maschmeyer G, Haas A, Bohme A (2005) [Update on therapy of invasive mycoses in hematology and oncology]. Dtsch Med Wochenschr 130: 1381-1384
13. Segal BH, Almyroudis NG, Battiwalla M et al (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44: 402-409
14. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7-14
15. McLintock LA, Jones BL (2004) Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol 126: 289-297
16. Viscoli C, Paesmans M, Sanz M et al (2001) Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 32: 1532-1537
17. Gotzsche PC, Johansen HK (2002) Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev: CD002033
18. Goodman JL, Winston DJ, Greenfield RA et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326: 845-851
19. Slavin MA, Osborne B, Adams R et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171: 1545-1552
20. Marr KA, Seidel K, Slavin MA et al (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96: 2055-2061
21. Schaffner A, Schaffner M (1995) Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 172: 1035-1041
22. Winston DJ, Chandrasekar PH, Lazarus HM et al (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118: 495-503
23. Glasmacher A, Comely O, Ullmann AJ et al (2006) An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57: 317-325
24. Marr KA, Crippa F, Leisenring W et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103: 1527-1533
25. Marr KA, Leisenring W, Crippa F et al (2004) Cyclophosphamide metabolism is affected by azole antifungals. Blood 103: 1557-1559
26. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G (1993) Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31: 973-984
27. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J (1991) A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27: 369-376
28. Penack O, Schwartz S, Martus P et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 17: 1306-1312
29. Kelsey SM, Goldman JM, McCann S et al (1999) Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23: 163-168
30. Comely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359
31. Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347
32. Mattiuzzi GN, Alvarado G, Giles FJ et al (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50: 143-147
33. van Burik J-AH, Ratanatharathorn V, Stepan DE et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407-1416
34. de Pauw BE (2005) Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41: 1251-1253
35. Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41: 1242-1250
36. Hebart H KL, Klingebiehl T et al (2004) PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: preliminary results of a prospective study. ASH Annual Meeting Abstracts 104: 192
37. No authors listed (1989) Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 86: 668-672
38. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: 101-111
39. Wingard JR (2004) Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39 (Suppl 1): S38-S43
40. Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340: 764-771
41. Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135: 412-422
42. Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225-234
43. Jorgensen KJ, Gotzsche PC, Johansen HK (2006) Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev: CD004707
44. Jorgensen KJ, Johansen HK, Gotzsche PC (2006) Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 7: 3
45. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415
46. Bowden R, Chandrasekar P, White MH et al (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35: 359-366
47. Stevens DA, Kan VL, Judson MA et al (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30: 696-709
48. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V (2005) Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 56 (Suppl 1): i39-i48
49. Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39: 1563-1571
50. Caillot D, Couaillier JF, Bernard A et al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19: 253-259
51. Masood A, Sallah S (2005) Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 29: 493-501
52. Bow EJ (2006) Of Yeasts and Hyphae: A Hematologist's approach to antifungal therapy. Hematology Am Soc Hematol Educ Program 51: 361-367
53. Kontoyiannis DP, Bodey GP, Mantzoros CS (2001) Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44: 125-135
54. Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366: 1435-1442
55. Pappas PG, Rex JH, Sobel JD et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38: 161-189
56. Wingard JR, Nichols WG, McDonald GB (2004) Supportive care. Hematology Am Soc Hematol Educ Program 55: 372-389
57. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ (2006) Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Clin Infect Dis 117: 711-716
58. Walmsley S, Devi S, King S et al (1993) Invasive Aspergillus infections in a pediatric hospital: a ten year review. Pediatr Infect Dis J 12: 673-682
59. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V (2003) The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 33: 453-460
60. Mennink-Kersten MASH, Verwej PE (2006) Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin N Am 20: 711-727
61. Groll AH, Ritter J (2005) Diagnose und Therapie von Pilzinfektionen und der Pneumocystis-Pneumonie bei Kindern und Jugendlichen mit neoplastischen Erkrankungen. Klin Padiatr 217(Suppl 1): S37-S66
62. Blyth CC, Palasanthiran P, O'Brien TA (2007) Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 119: 772-784